Because it matters.

Accelerating the journey from data to medicine.


More Effective Drugs.


BenevolentAI is creating and applying AI technologies to transform the way medicines are discovered, developed, tested and brought to market.  The Company has developed the Benevolent Platform™ - a leading computational and experimental discovery platform used by BenevolentAI scientists to find new ways to treat disease and personalise drugs to patients.

The Benevolent Platform™ focuses on four key areas of drug discovery and development: Knowledge and Reasoning, Target Identification, Molecular Design and Precision Medicine


For every patient.

I work here because I want to transform drug discovery to serve every patient equally. I want to develop AI that benefits society
— Alix. Data Scientist, New York
Alix Lacoste.jpg

Better Data Decision Making.


BenevolentAI seeks to improve patient’s lives by applying technology designed to generate better data decision making and in doing so lower drug development costs, decrease failure rates and increase the speed at which medicines are generated.  

Mark Rackham 1.jpg

Finding a treatment for Amyotrophic Lateral Sclerosis (ALS)

Read more →

Where it happens.



We're headquartered in London’s ‘Knowledge Quarter,’ where our neighbours include Google, Facebook, the Alan Turing Institute, the Francis Crick Institute, UCL and the Wellcome Trust.
Get there →


We operate our own state-of-the-art BenevolentAI drug discovery and development facility, on the world famous Babraham Research Campus, Cambridge UK.
Get there →

New York

Our New York office opened this year and looks out onto the Brooklyn Bridge. The team is twenty-strong and growing, and works side-by-side within squads that span all our locations.
Get there →


We have a small but perfectly formed team of engineers in Antwerp, Belgium, led by Benevolent's SVP Technology.
Get there →


Lately at BenevolentAI.



Artificial intelligence identifies existing drugs that may reduce sight loss from macular degeneration

The initial results from an artificial intelligence project show a number of existing drugs have the potential to reduce sight loss from age-related macular degeneration, the leading cause of sight loss. Action Against AMD, a research collaboration formed by four UK sight loss charities (Blind Veterans UK, Fight for Sight, the Macular Society and Scottish War Blinded), partnered with artificial intelligence company BenevolentAI to carry out the research.

AMD BenevolentAI.png